Ribozyme RPI.4610

Known as: RPI-4610, RPI.4610, RPI4610 
A nuclease-stabilized synthetic ribozyme (ribonucleic acid enzyme) with potential anti-angiogenesis activity. Ribozyme RPI.4610 specifically… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2012
0119982012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND Serum and plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis in patients with… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2007
Review
2007
The prognosis for any patient with progressive or recurrent invasive transitional cell carcinoma remains poor. In this context… (More)
  • table 1
  • table 2
Is this relevant?
2004
2004
RPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The purpose of… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
1998
1998
  • Gene Therapy
  • 1998
Vascular Endothelial Growth Factors (VEGF) are the latest focus for two gene therapy companies. Human Genome Sciences(Rockville… (More)
Is this relevant?